Cytokinetics Inc (CYTK)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$62.17

Buy

$62.34

arrow-down$-0.70 (-1.11%)

Prices updated at 20 Mar 2026, 18:11 EDT

Prices minimum 15 mins delay

Prices in USD

Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

NASDAQ

-1.64%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. John T. Henderson, M.B.

CEO

Mr. Robert I. Blum

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

673

Head office

350 Oyster Point Boulevard

South San Francisco

United States

94080

+1 650 624-3000

investor@cytokinetics.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Ms. B. Lynne Parshall, Esq.,J.D. Independent Director	0.09m
Dr. John T. Henderson, M.B. Chairman of the Board	0.12m
Ms. Nancy J. Wysenski Independent Director	0.08m
Mr. Robert I. Blum Director, President and Chief Executive Officer	0.83m
Dr. Wendell D. Wierenga,PhD Independent Director	0.09m
Dr. Edward M. Kaye, M.D. Independent Director	0.07m
Mr. James M. Daly Independent Director	-
Mr. Robert E. Landry Independent Director	-
Mr. Jeffrey J. Hessekiel Executive Vice President, Chief Legal and Administrative Officer	-
Mr. Sung H. Lee Executive Vice President, Chief Financial Officer and Principal Accounting Officer	0.55m
Ms. Muna Bhanji, Ph. Independent Director	0.07m
Dr. Robert A. Harrington, M.D. Independent Director	0.06m
Dr. Fady Ibraham Malik, M.D.,PhD Executive Vice President, Research and Development	0.61m
Mr. Andrew M. Callos Executive Vice President and Chief Commercial Officer	0.56m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
T. Rowe Price Investment Management,Inc.	27,106,776
BlackRock Inc	15,525,747
FMR Inc	12,807,752
Fidelity Management and Research Company	12,807,752
Vanguard Group Inc	12,048,131

Director dealings

Date chevron-l-regular chevron-r-regular	Action
29 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.